VIDEO: Aflibercept 8 mg shows comparable safety to aflibercept 2 mg at 96 weeks
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston discusses 96-week safety and tolerability data for aflibercept 8 mg.
According to Weng, the pooled safety analysis included 1,773 patients who received more than 10,000 injections over approximately 2 years and investigated aflibercept 8 mg vs. aflibercept 2 mg for the treatment of wet age-related macular degeneration and diabetic macular edema. Data were pooled through week 44 of the phase 2 CANDELA study and week 96 of the phase 3 PULSAR and PHOTON trials.
“Aflibercept 8 mg demonstrated comparable safety to aflibercept 2 mg for up to 96 weeks across the pooled CANDELA, PULSAR and PHOTON trials,” Weng said. “It’s also encouraging that these outcomes are very much in line with what’s been reported so far post-approval. That being said, aflibercept 8 mg is still a relatively new addition to our toolboxes, and continued vigilance with real-world use is critical.”
Collapse
Weng C. Pooled safety analysis of aflibercept 8 mg for up to 96 weeks in the CANDELA, PHOTON, and PULSAR trials. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts